REGENERON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent
REGENERON PHARMACEUTICALS, INC. (REGN) reported Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent of 0.00% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-07.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities · last filed 2020-02-07
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2019 was 0.00%.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2018 was 0.00%, a 100.00% decline from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2017 was 2.60%, a 7.14% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2016 was 2.80%, a 12.50% decline from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month |
|---|---|
| 2019-12-31 | 0.00% 10-K · filed 2020-02-07 |
| 2018-12-31 | 0.00% 10-K · filed 2020-02-07 |
| 2017-12-31 | 2.60% 10-K · filed 2020-02-07 |
| 2016-12-31 | 2.80% 10-K · filed 2019-02-07 |
| 2015-12-31 | 3.20% 10-K · filed 2018-02-08 |
| 2014-12-31 | 0.00% 10-K · filed 2017-02-09 |
| 2013-12-31 | 0.00% 10-K · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |